WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:
Conference Details:
| 13th Annual ROTH Technology Conference | |
| Date: | Tuesday, November 19th – Wednesday 20th |
| Format: | 1x1 Meetings |
| Location: | The Hard Rock Hotel, New York City |
| Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum | |
| Date: | Thursday, November 21st |
| Format: | 1x1 Meetings |
| Location: | The Westin NY Grand Central, New York City |
To request a meeting or for more details about the conferences please reach out to your institutional contact or email.
About OptimizeRx
OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 2 million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary digital point-of-care network, as well as mass digital communication channels, OptimizeRx helps life sciences organizations engage and support their customers.
For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.
OptimizeRx Contact
Andy D’Silva, SVP Corporate Finance
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$8.45 |
| Daily Change: | 0.27 3.30 |
| Daily Volume: | 141,715 |
| Market Cap: | US$155.650M |
December 23, 2024 November 13, 2024 September 09, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
